Aytu BioPharma, Inc. (AYTU) 株式分析

企業概要

Aytu BioPharma, Inc. is a pharmaceutical enterprise dedicated to the commercialization of novel therapeutics within the United States and international markets, with a specific focus on prescription products for attention deficit hyperactivity disorder (ADHD) and other medical indications. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its specialization in developing and marketing niche pharmaceutical solutions rather than broad-market mass production. Currently, the entity employs a workforce of 82 individuals and holds a total market capitalization of $27.48M, while reporting a trailing twelve-month revenue of $62.64M. These financial figures indicate that Aytu BioPharma functions as a small-cap entity with a modest operational footprint, reflecting a business model that relies on high-margin specialty drugs to generate revenue despite its limited scale and employee base.

財務健全性

The company reported a revenue of $62.64M over the trailing twelve months, yet it simultaneously recorded a net income loss of $-24,559,000, revealing a significant gap where high operating costs or research expenses are substantially eroding profitability. This structural deficit is partially offset by an EBITDA of $4.03M, suggesting that while accounting for non-cash items and interest, the core operational cash generation remains positive despite the reported net loss. However, the free cash flow stands at $-6,978,375, indicating that the company is currently consuming cash reserves to fund operations and growth initiatives rather than generating excess liquidity. The gross margin is reported at 66.8%, which points to a high-margin product portfolio typical of specialty pharmaceuticals, whereas the operating margin sits at -13.0% and the profit margin at -39.0%, highlighting substantial overhead pressures or R&D investments impacting the bottom line. On the balance sheet side, the company holds $30.02M in cash against $22.10M in debt, resulting in a debt-to-equity ratio of 155.63, which suggests a highly leveraged capital structure relative to shareholder equity. Liquidity is constrained by a current ratio of 1.16, implying that current assets barely cover current liabilities, which may require careful management of working capital to maintain solvency. Furthermore, the return on equity is -109.2% and the return on assets is -0.2%, metrics that collectively reveal that management is currently unable to generate positive returns on the capital deployed by shareholders or the asset base.

バリュエーション評価

Valuation metrics for Aytu BioPharma present a complex picture, with a trailing P/E ratio of N/A due to the net losses, contrasted by a forward P/E of 15.06 which implies market expectations for future earnings normalization or recovery. The price-to-book ratio stands at 1.93, indicating that the market values the company at a premium of roughly 93% above its tangible book value, likely reflecting the intangible value of its intellectual property and drug pipeline. Alternative valuation measures such as a price-to-sales ratio of 0.44 and an EV/EBITDA of 4.86 provide context for the company's pricing relative to its revenue and adjusted earnings power, suggesting a valuation that is not prohibitively expensive relative to sales but is sensitive to earnings volatility. The stock's trading range over the past year spans from a low of $0.96 to a high of $3.07, and based on the forward P/E context, the current valuation sits within a range that reflects significant upside potential from the 52-week low if earnings improve. The beta coefficient is recorded at 0.28, which indicates that the stock's price volatility is substantially lower than the broader market, making it less sensitive to general market fluctuations and more driven by company-specific developments or sector trends.

Growth & Income

Regarding growth trajectories, the company experienced a revenue decline of -6.5% year over year, while earnings growth is listed as N/A due to the lack of profitability, a situation that implies earnings are not currently expanding alongside revenue but are instead contracting or remaining negative. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically available for reinvestment or retained to service debt rather than being distributed to shareholders. Consequently, the firm's strategy focuses on retaining capital to fund the commercialization of its novel therapeutics and to navigate the cash burn associated with its current free cash flow position rather than providing immediate income to investors. The overall growth and income profile for Aytu BioPharma is characterized by negative revenue momentum, a complete absence of dividend income, and a reliance on future operational improvements to shift from a cash-consumption to a cash-generation model.